China Antibody (03681.HK) announced that on December 4, the Phase 1b clinical trial of SM17 (a humanized anti-IL-25 receptor monoclonal antibody for injection) for treating moderate to severe atopic dermatitis has completed the enrollment of all 32 patients in China.

This Phase 1b clinical trial completed its first patient dosing on June 11, and the last visit for the final subject (LSLV) is expected to be completed by the end of March next year. The group anticipates obtaining topline data in the first quarter of next year. Previously, the company had completed Phase I clinical trials of SM17 in the usa and china.